The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy

Cancer

Volumn 83, Issue 8, 1998, Pages 1561-1566

  Diamond, Terrence ^a   Campbell, Joanne ^a   Bryant, Carl ^a   Lynch, William ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

Combined androgen blockade; Disseminated; Osteoporosis; Prostate carcinoma

Indexed keywords

ANDROGEN; CALCIFEDIOL; CALCIUM; ETIDRONIC ACID; OSTEOCALCIN; PARATHYROID HORMONE; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CALCIUM BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; SPINE FRACTURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AMINO ACIDS; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; CALCIUM; CARCINOMA; DENSITOMETRY, X-RAY; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; EVALUATION STUDIES; FEMUR NECK; FLUTAMIDE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LONGITUDINAL STUDIES; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOCALCIN; PARATHYROID HORMONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REMISSION INDUCTION; TESTOSTERONE; TOMOGRAPHY, X-RAY COMPUTED; VITAMIN D;

EID: 0032531859     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981015)83:8<1561::AID-CNCR11>3.0.CO;2-Z     Document Type: Article

References (31)

1. McLeod DG. Hormonal therapy in the treatment of carcinoma of the prostate. Cancer 1995;75:1914.
2. Garnick MB. Hormonal therapy in the management of prostate cancer: from Huggins to the present, Urology 1997; 49(Suppl 3a):5-15.
3. Bianchi S, Fedele L, Vignali M, Galbiati E, Cherubini R, Ortolani S. Effects on bone mineral density of 12-month goserelin treatment in over 40-year old women with uterine myomas. Calcif Tissue Int 1995;57:78-80.
4. Goldray D, Weisman Y, Jaccard N, Merdler C, Chen J, Matzkin H. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 1993;76:288-90.
5. Clarke NW, McLure J, George NJR. The effects of orchiectomy on skeletal metabolism in metastatic prostate cancer. Scand J Urol Nephrol 1993;27:475-83.
6. Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostatic cancer treated with orchiectomy and with estrogen. Calcif Tissue Int 1995;57:97-9.
7. Mc Grath SA, Diamond T. Osteoporosis as a complication of orchiectomy in two elderly men with prostatic cancer. J Urol 1995;154:535-6.
8. Carlstrom K, Stege R, Henriksson P, Pousette A. Effects of endocrine treatment on bone mineral markers in patients with prostatic cancer [abstract]. Scand J Urol Nephrol 1994; 161:28-9.
9. Percival RC, Urwin GH, Harris S, Yates AJ, Williams JL, Beneton M, et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987;13:41-6.
10. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997;157:439-44.
11. Collinson MP, Tyrell CJ, Hutton C. Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate. Calcif Tissue Int 1994;54:327-8.
12. Maillefert JF, Sibilia J, Kuntz JL, Tavernier C. Gonadotrophin-releasing hormone agonists induce osteoporosis. Br J Rheumatol 1994;33:1199-200.
13. Horan AH. Fractures ascribable to osteoporosis following LHRH antagonism for carcinoma of the prostate: a preliminary survey. J Bone Miner Res 1993;8:763 [abstract].
14. Townsend M, Sanders WH, Northway RO, Graham SD. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997;79:545-50.
15. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
16. Larnach TA, Boyd SJ, Smart RC, Butler SP, Rohl PG, Diamond T. Reproducibility of lateral spine scans using dual energy Xray absorptiometry. Calcif Tissue Int 1992;51:255-8.
17. Diamond T, McGuigan L, Barbagallo S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 1995;98:459-63.
18. Orwoll ES, Oviatt SK, Mann T. The impact of osteophytic and vascular calcifications on vertebral bone mineral density measurements in men. J Clin Endocrinol Metab 1990; 70:1202-7.
19. Jones G, Nguyen T, Sambrook P, Kelly PJ, Eisman JA. Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ 1994;309:691-5.
20. Jackson JA, Kleerekoper M. Osteoporosis in men: diagnosis, pathophysiology and prevention. Medicine 1990;69:137-52.
21. Vermeulen A, Kaufman JM. Role of the hypothalamo-pituitary function in the hypoandrodrogenism of healthy aging. J Clin Endocrinol Metab 1992;75:704-6.
22. Jackson JA, Kleerekoper M, Parfitt AM, Rao DS, Villanaueva AR, Frame B. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab 1987;65:53-8.
23. Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodelling. N Engl J Med 1995;332:305-11.
24. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink D. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989;69:523-7.
25. Reinbold WD, Genant HK, Reiser UJ, et al. Bone mineral content in early postmenopausal and postmenopausal osteoporotic women: comparison of measurement methods. Radiology 1986;160:469-78.
26. Delmas P. Bisphosphonates in the treatment of bone disease. N Engl J Med 1996;24:1836-7.
27. Rodan GA, Fleisch HA. Bisphosphonates: mechanism of action. J Clin Invest 1996;12:2692-6.
28. Vorreuther R. Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostate cancer. A pilot study on clodronate. Br J Urol 1993;72:792-5.
29. Mukherjee T, Barad D, Yurk R, Freeman R. A randomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment. Am J Obstet Gynecol 1996;175: 105-9.
30. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone disease. N Engl J Med 1996;335:1785-91.
31. Yu-cheng S, Geldoff AA, Newling DWW, Rao BR. Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates. J Urol 1995;148:1270.